Aurinia Pharmaceuticals Inc. has added two potential drugs to its pipeline targeting autoimmune and kidney-related diseases through an acquisition and a licensing deal. Victoria, British Columbia-based Aurinia is building on its first ever FDA approval at the beginning of the year, for Lupkynis (voclosporin) for treating active lupus nephritis in adults.
Organ transplantation is often a life-saving intervention whose success is mediated by the host's immune system. Immune-mediated rejection of an organ transplant destroys the transplanted organ or tissue and can be fatal.
RSS
